Novo Nordisk

Popular insulin meets target in real-world studyNovo Nordisk’s DEVOTE study reveals interesting findings.
How diabetes is linked to gut bacteriaGiven this abundance of nonhuman species living on and within our bodies, it is not surprising that there is a link between specific bacteria to systemic and ocular disease—including diabetes and diabetes-related eye disease.
Partnership aims to make insulin more affordableCVS, Novo Nordisk launch a prescription savings program to help patients afford essential medications.
Nine ways to help diabetic patients complyGetting diabetic patients to adhere to medication and dietary changes can be difficult. Here are some tips from experts.
New therapies show promise in treating diabetes
New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Using OCT with your diabetes patientsOCT is one of the best way to assess patients for the presence of diabetic macular edema (DME)
Diabetic patients challenge insulin makersIn the latest flap over the high cost of drugs, diabetes patients filed a class-action lawsuit against insulin makers.
Insulin makers accused of price collusionU.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest in concerns over insulin prices.
Pharma company keeps pace with rise of diabetesNovo Nordisk’s new diabetes drug production facility in Clayton, N.C., will ensure production capacity for these drugs in the United States for the decade ahead.
Major diabetes drug cuts heart attack riskNew data from Novo Nordisk will help its Victoza (liraglutide) for type 2 diabetes better compete against Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin). Victoza significantly reduced the combined incidence of heart attack, stroke and cardiovascular death in high-risk Type 2 diabetes patients, according to Novo Nordisk